Innovation Showcase

Eyedaptic

Eyedaptic’s unique Software for retina-related vision loss, embedded in Augmented Reality glasses, simulate natural vision for suffers with AMD and central vision loss, to restore a complete field of vision to help sufferers lead fuller lives. Equipped with patent pending software the Company’s solution optimizes the sufferer’s functional peripheral vision to help restore the entire scene for the wearer. Unlike other visual aids that use only magnification, thereby reducing the user’s field of vision, our solution maximizes their field of view. The camera captures the surroundings, manipulates the pixels and re-displays the image where the user can see it. The adapted view for the wearer takes advantage of the part of the retina that still functions well so the user sees the entire scene.

Eyenovia

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. The Optejet™ piezo-print smart delivery platform is disruptive to the 100 year legacy eyedropper paradigm. The Optejet(tm) dispenser gently and accurately coats the ocular surface with a micro-dose of medication, while also potentially reducing dose-related ocular toxicity and side effects. Recently, we reported that a single microdose of latanoprost, delivering 75% less drug and preservative than a standard eyedrop, achieved 29% IOP lowering from baseline versus the 26% effect seen in other studies of conventional eyedrops. In addition to CACG, Eyenovia’s pipeline is currently focused on late-stage therapies for myopia progression, mydriasis and other eye diseases.

MacuLogix

MacuLogix, equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD). AMD is a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in at least 25% of patients. The company's AdaptDx automated dark adaptometer measures a patient's ability to adjust from light to darkness. This dark adaptation function is compromised from the earliest stages of disease, indicating the presence of AMD with 90% accuracy at least three years before drusen are visible. To help achieve its vision of eliminating preventable blindness caused by AMD, MacuLogix partners with eye care professionals to provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx.

OcuMedic

Timed Drug Delivery to the Eye via a Contact Lens/Clear Corneal Bandage with 7 Day wear. The technology rests on 10 issued patents, and a recent Freedom to Operate (FTO) opinion. Efficacy has been proven in an animal model. The intellectual property teaches a novel therapeutic contact lens with memory capable of controlled release of first line ophthalmic agents, both anti-inflammatory and antibiotic.

Ocunexus

Ocunexus is a clinical stage company developing compounds shutting down the inflammasome pathway of inflammation. Physiologically hemichannels are continuously forming in cell membranes and remain closed until docked with a neighboring cell at which point they open to form gap junctions. In multiple disease states the connexin43 (Cx43) hemichannel protein is overexpressed and the hemichannel opens prematurely allowing for ATP to enter the extracellular space. ATP assembles the innate inflammasome (NLRP3) pathway of inflammation resulting in release and continuing cycling of multiple proinflammatory cytokines. Ocunexus lead compound is Xiflam a Phase 2B ready orally administered Cx43 inhibitor in development for Geographic Atrophy and Diabetic Retinopathy.

Ocunexus has also developed a Peptide which is a Cx43 hemichannel inhibitor for intravitreal use in posterior segment disease.

Website-Logo---SightGlass

SightGlass Vision

SightGlass Vision, Inc. is a clinical-stage medtech startup company focused on ending myopia.

SilkTech Biopharmaceuticals

Silk Technologies is developing SDP-4, a novel biotherapeutic, designed to treat the signs and symptoms of Dry Eye Disease (DED) through a dual-mechanism of action. Pre-clinical data demonstrates SDP-4 inhibits inflammatory pathways known to drive DED symptomatology, while simultaneously enhancing spreading and wetting of the ocular surface to improve patient comfort during use due to the protein chemistry of the product. Silk Technologies has SDP-4 currently in pre-clinical development with an anticipated Phase II clinical trial starting the first quarter of 2019. The SDP-4 eye drop is preservative free, aqueous, and highly stable at room temperature. The company has issued patents protecting their proprietary silk-derived protein material, and is currently supported through private equity and Federal Government grant funding.

Dry Eye Showcase

Johnson & Johnson Vision

Johnson & Johnson Vision is committed to improving and restoring sight for patients worldwide. Through their world-leading ACUVUE® Brand Contact Lenses portfolio, newly acquired cataract surgery, laser refractive surgery (LASIK) and consumer eye health businesses, they now serve more than 60 million patients a day across 103 countries. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 8,400 employees worldwide.

Kala Pharmaceuticals

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala’s first approved is INVELTYS, the first and only corticosteroid for the treatment of inflammation and pain following ocular surgery. Kala’s lead pipeline candidate is KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the FDA and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.

Novaliq

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing the needs of eye disease patients. Lead assets in clinical development are: CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of dry eye disease with a demonstrated early onset of action and an excellent tolerability; and NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction. NovaTears® water-free eye drops for dry eye have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Headquartered in Heidelberg/Germany, Novaliq has an office in Cambridge, MA/USA. Long-term shareholder is dievini Hopp BioTech Holding

Oyster Point Pharma

Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production by delivering therapy as a nasal spray in patients with Dry Eye Disease (DED).

Sight Sciences

In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, TRAB®360 and VISCO360® for use by ophthalmologists. Its non-surgical product portfolio consists of its TearCare™ technologies for use by ophthalmologists and optometrists.

Glaucoma Showcase

Allergan

Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world.  The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.

Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.

Mati Therapeutics

Mati is developing the Evolute platform - a non-invasive sustained drug delivery platform using punctal plugs as a delivery device. Products using the Evolute system are being developed for glaucoma, dry eye, allergy and inflammation. In prior studies, the Stable Fit punctal plug design has shown retention rates of 92% and 96% over a 12 week follow up period. Mati is currently conducting a Phase II trial of nepafenac in patients undergoing cataract surgery and positive interim results were announced in September. Mati will soon be undertaking a study using travoprost in patients with glaucoma and ocular hypertension and further plans to develop a steroid for post-cataract inflammation. This technology platform is well-supported with 114 patents issued in major countries around the world.

Vivid Vision

Vivid Vision is a medical device company providing a virtual reality platform for measuring and treating diseases of vision. Vivid Vision currently offers both in-office and at-home products for the treatment of binocular vision disorders that are available to patients through hundreds of clinical providers globally as well as an upcoming mobile perimeter for monitoring glaucoma.

Imaging and Diagnostics Showcase

Carl Zeiss Meditec

Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.

Heidelberg

Heidelberg Engineering is an imaging solutions company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. The company’s products are used by ophthalmologists and optometrists to scan patients’ eyes for signs of disease and to assist in the management of patients found to have disease.

The company’s core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography, software image analysis and IT solutions for image management.

Heidelberg Engineering is a privately held company, headquartered in Heidelberg, Germany. The company distributes its products through a network of subsidiaries and distribution partners in most countries of the world.

OCULUS

OCULUS: Tradition since 1895
For more than 120 years, OCULUS has been a partner for eye care professionals around the world. OCULUS, Inc. (USA) was founded in 1999. Combining the finest German engineering with exceptional customer support, we understand the importance of continuous operation of your devices. With service centers located in Washington and Florida, OCULUS provides reliable, fast and customer-friendly service from 8 am to 8 pm EST. We provide ongoing training and educational resources, which are accessible 24/7 in our online library or offline during many in house training sessions throughout the year.

With our products, such as the Pentacam®, Keratograph® 5M, and Easyfield® C, we have established a gold standard in ophthalmic diagnostic devices. Our customers and their satisfaction is our responsibility.

Topcon

Topcon Medical Systems (TMS) is a leading developer and supplier of diagnostic equipment for the ophthalmic community.

Topcon's mission is to make impossible ideas possible, by constantly developing new optical and measurement technologies. Our goal is simple: to provide you with the most innovative equipment so that you can better serve your patients.

For over 40 years, TMS has been leading the way with the most technically advanced instrumentation in the marketplace. Our product line comprises the largest selection of precision instruments from one manufacturer ... providing products for a wide range of applications, including imaging, diagnostic, refractive, surgical, and delivery. Whatever your particular instrument requirements, Topcon has the innovative solution you need.

Topcon Medical Systems is a wholly owned subsidiary of Topcon Corporation of Tokyo, Japan.